Guidelines for the diagnostic and treatment of acromegaly;Recommandations pour le diagnostic et le traitement de l'acromegalie

Medecine et Hygiene

Volumn 57, Issue 2242, 1999, Pages 306-316

  Gaillard, Rolf C ^a  

^a Division d'Endocrinologie   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; OCTREOTIDE; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; ALGORITHM; EARLY DIAGNOSIS; GROWTH HORMONE BLOOD LEVEL; HUMAN; HUMAN CELL; HUMAN TISSUE; LONG TERM EXPOSURE; MORBIDITY; PRACTICE GUIDELINE; REVIEW; RISK BENEFIT ANALYSIS;

EID: 0033540640     PISSN: 00256749     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Alexander L, Appleton D, Hall R, Ross WM, Wilkinson R. Epidemiology of acromegaly in the Newcastle region. Clin Endocrinol (Oxf) 1980; 12: 7-9.
2. Bengtson B-A, Eden S, Ernest I, Oden A, Sjogren B. Epidemiology and long-term survival in acromegaly. Acta Med Scand 1988; 223: 327-35.
3. van der Lely AJ, de Herder WW, Janssen JAMJL, Lamberts SWJ. Acromegaly: The significance of serum total and free IGF-I and IGF-binding protein-3 in diagnosis. J Endocrinol 1997; 155: S9-S13.
4. Chapman IM, Hartman ML, Straume M, Johnson ML, Veldhuis JD, Thorner MO. Enhanced sensitivity growth hormone (GH) chemiluminescence assay raveals lower postglucose nadir GH concentrations in men than in women. J Clin Endocrinol Metab 1994; 78: 1312-9.
5. Melmed S, Ho K, Klibanski A, Reichlin S, Thorner M. Clinical reriew 75: Recent advances in pathogenesis, diagnosis, and management of acromegaly. J Clin Endocrinol Metab 1995; 80: 3395-402.
6. Bates AS, Van't Hoff W, Jones JM, Clayton RN. An audit of outcome of treatment in acromegaly. QJ Med 1993; 86: 293-9.
7. Orme SM, McNally R, Staines A, Cartwright RA, Belchetz PE. Mortality and cancer incidence in acromegaly: A retrospective cohort study. Proceedings of the International Society for Endocrinology, San Francisco. June 1996, p. 2-454.
8. Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ, Ibbertson A. Determinants of clinical outcome and survical in acromegaly. Clin Endocrinol (Oxf) 1994; 41: 95-102.
9. Clayton RN. New developments in the management of acromegaly. Should we achieve absolute biochemical cure? J Endocrinol 1997; 155: S23-S9.
10. Fahlbusch R, Honegger J, Buschfelder M. Evidence supporting surgery as treatment of choice for acromegaly. J Endocrinol 1997; 155: S53-S5.
11. Landolt AM, Illig R, Zapf J. Surgical treatment of acromegaly. In: Lamberts SWJ, ed. Sandostatin in the treatment of acromegaly. Berlin: Springer-Verlag, 1988; 23.
12. Frohman LA, Editorial: Acromegaly: What constitutes optimal therapy? J Clin Endocrinol Metab 1996; 81: 443-5.
13. Wrightson P, Rajasoorya C, Holdaway M, Scott J. Acromegaly: Factors affecting the longterm outcome after surgical treatment. J Clin Neurosc 1994; 1: 164-72.
14. Osman IA, James KA, Chatterjee S, Mathias D, Kendall-Taylor P. Factors determining the long-term outcome of surgery for acromegaly. Q J Med 1994; 87: 617-23.
15. Jenkins D, O'Brien I, Johnson A, Shakespear R, Sheppard MC, Stewart PM. The Birmingham pituitary database: Auditing the outcome of treament of acromegaly. Clin Endocrinol (Oxf) 1995; 43: 517-22.
16. Stevenaert A, Harris AG, Kovacs K, Beckers A. Presurgical octreotide treatment in acromegaly. Metabolism 1992; 41 (Suppl. 2): 51.
17. Chiodini PG, Luizzi A, Botalla L, Cremascoli G, Müller EE, Silvestrini F. Decrease plasma GH levels in acromegalics following CB 154 administration. J Clin Endocrinol Metab 1974; 38: 910.
18. Jaffe CA, Barkan AL. Treatment of acromegaly with dopamine agonists. Endocrinol Metab Clin North Am 1992; 21: 713-35.
19. Abs R, Verhelst J, Maiter D, Van Acker K, Nobels F, Coolens JL, et al. Cabergoline in the treatment of acromegaly: A study in 64 patients. J Clin Endocrinol Metab 1998; 83: 374-8.
20. Lombardi G, Colao AM, Ferone D, Samacchiaro F, Marzullo P, Di Sarno A, et al. CV 205-502 treatment in therapy resistant acromegalic patients. Eur J Endocrinol 1995; 132: 559-64.
21. Jaquet P. Evidence for dopamine agonists in the treatment of acromegaly. J Endocrinol 1997; 155: S59-S60.
22. Colao A, Ferone D, Marzullo P, Di Sarno A, Cerbone G, Samachchiaro F, et al. Effect of different dopaminergic agents in the treatment of acromegaly. J Clin Endocrinol Metab 1997; 82: 518-23.
23. Plewe G, Beyer J, Krause U, Neufield M, del Pozo E. Long-acting and selective suppression of GH secretion by somatostatin analog SMS 201-995 in acromegaly. Lancet 1984; 2: 782-7.
24. Liuzzi A, Oppizzi G. Evidence for octreotide subcutaneously in the treatment of acromegaly. J Endocrinol 1997; 155: S61-S5.
25. Flogstad AK, Halse J, Haldorsen T, Lancranjan I, Jervell J. Sandostatin in acromegalic patients: A dose-response study. J Clin Endocrinol Metab 1995; 80: 3601-7.
26. Lancranyan I, Bruns C, Grass P, Jaquet P, Jerwell J, Kendall-Taylor P, et al. Sandostatin 'LAR': A promising therapeutic tool in the management of acromegalic patients. Metabolism 1996; 45 (Suppl. 1): 67-71.
27. Flagstad AK, Halse JS. Lancranjan I, Marbach P, Bruns C, et al. Sandostatin LAR in acromegalic patients: Long term treatment. J Clin Endocrinol Metab 1997; 82: 23-8.
28. Robbins RJ. Editorial: Depot somatostatin analogs-a next first line therapy for acromegaly. J Clin Endocrinol Metab 1997; 82: 15-7.
29. Wass JAH . Evidence for the effectiveness of radiotherapy in the treatment of acromegaly. J Endocrinol 1997; 155: S57-S8.
30. Landolt AM, Haller D, Lomax N, Scheib S, Schubiger O, Siegfried J, et al. Stereotactic radiosurgery for recurrent surgically treatment acromegaly: Comparison with fractionated radiotherapy. J Neurosurg 1998; 88: 1002-8.